In 2020, Swiss-based Novartis was the second largest pharmaceutical company worldwide based on revenue from prescription drugs. In 2021, Novartis made some 51.6 billion U.S. dollars of revenue in total, a significant increase compared to the previous year. The company made some significant restructuring measures since 2015, so that today there are only two major core businesses left.
U.S and Europe are the key
Novartis is divided into two segments: Pharmaceuticals (now called Innovative Medicines), and Sandoz. The Pharmaceuticals segment is responsible for the largest part of the total revenue – around 42 billion U.S. dollars. From a regional point of view, Novartis generates the overwhelming part of its revenue in the United States and in Europe. In 2021, about 20.2 billion U.S. dollars were generated in Europe and some 16.8 billion dollars in the United States. Among Novartis’ top products are immunomodulating agent Cosentyx and cardiovascular drug Entresto. It is estimated that Novartis reaches nearly 770 million patients worldwide through its products.
Research and development
Nearly 10 billion U.S. dollars – almost 19 percent of Novartis’ total revenue – was spent on research and development in 2021. R&D is a major issue for the top pharmaceutical companies because patent expirations can lead to massive revenue losses. Thus, only new medicines with at least a few years of exclusivity can ensure progress and profit. At Novartis, such growth products make up around one third of its total revenues.
This text provides general information. Statista assumes no
liability for the information given being complete or correct.
Due to varying update cycles, statistics can display more up-to-date
data than referenced in the text.
In the following 5 chapters, you will quickly find the 25 most important statistics relating to "Novartis".